Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia

No abstract is available for this paper.

• Publication year

  2008

• Venue

  The Pharmacogenomics Journal

• Publication date

  2008-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/sj.tpj.6500474PMID 17726453
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.

  2007cited by this paper
• Weight gain associated with the α2a‐adrenergic receptor −1291 C/G polymorphism and olanzapine treatment

  2006cited by this paper
• Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.

  2006cited by this paper
• The 5-HT2C receptor and antipsychoticinduced weight gain – mechanisms and genetics

  2006cited by this paper
• Consistent Effects of Genes Involved in Reverse Cholesterol Transport on Plasma Lipid and Apolipoprotein Levels in CARDIA Participants

  2006cited by this paper
• Impact of APOA5/A4/C3 genetic polymorphisms on lipid variables and cardiovascular disease risk in French men.

  2006cited by this paper
• Pharmacogenomics of cholesterol-lowering therapy.

  2006cited by this paper
• Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis

  2005cited by this paper
• Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients.

  2005cited by this paper
• Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

  2005cited by this paper
• Second-Generation (Atypical) Antipsychotics and Metabolic Effects

  2005cited by this paper
• Weight gain with antipsychotic drugs: the role of the 5-HT2C receptor (HTR2C) and other genes.

  2005cited by this paper
• APOA5 polymorphisms influence plasma triglycerides in young, healthy African Americans and whites of the CARDIA Study Published, JLR Papers in Press, December 16, 2004. DOI 10.1194/jlr.M400437-JLR200

  2005cited by this paper
• Genetic Basis of Atherosclerosis: Part II: Clinical Implications

  2004cited by this paper
• The effects of antipsychotic therapy on serum lipids: a comprehensive review.

  2004cited by this paper
• Impact of the Pro12Ala polymorphism of the PPAR-gamma2 gene on serum triacylglycerol response to n-3 fatty acid supplementation.

  2003cited by this paper
• Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain.

  2003cited by this paper
• Muscarinic mechanisms of antipsychotic atypicality.

  2003cited by this paper
• Interaction effect of Serine447Stop variant of the lipoprotein lipase gene and C-514T variant of the hepatic lipase gene on serum triglyceride levels in young adults: the Bogalusa Heart Study.

  2003cited by this paper
• Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

  2002cited by this paper
• Genetic and environmental determinants of plasma high density lipoprotein cholesterol and apolipoprotein AI concentrations in healthy middle‐aged men

  2002cited by this paper
• Common haplotypes in five genes influence genetic variance of LDL and HDL cholesterol in the general population.

  2002cited by this paper
• Associations of LPL and APOC3 gene polymorphisms on plasma lipids in a Mediterranean population: interaction with tobacco smoking and the APOE locus.

  2002cited by this paper
• Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective Disorder

  2002cited by this paper
• The apoAI-CIII-AIV gene cluster.

  2001cited by this paper
• Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials.

  2001cited by this paper
• Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine.

  2001cited by this paper
• Contribution of Apolipoprotein C-III Gene Variants to Determination of Triglyceride Levels and Interaction With Smoking in Middle-Aged Men

  2000cited by this paper
• Variation of Candidate Genes in Triglyceride Metabolism

  2000cited by this paper
• Genetic screening of the lipoprotein lipase gene for mutations associated with high triglyceride/low HDL-cholesterol levels

  2000cited by this paper
• Two common mutations (D9N, N291S) in lipoprotein lipase: a cumulative analysis of their influence on plasma lipids and lipoproteins in men and women

  1999cited by this paper
• The Role of Serotonin in Antipsychotic Drug Action

  1999cited by this paper
• Functional variants in the lipoprotein lipase gene and risk cardiovascular disease.

  1999cited by this paper
• Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine

  1996cited by this paper
• UKPDS 19: heterogeneity in NIDDM: separate contributions of IRS-1 and beta 3-adrenergic-receptor mutations to insulin resistance and obesity respectively with no evidence for glycogen synthase gene mutations. UK Prospective Diabetes Study.

  1996cited by this paper
• UKPDS 19: Heterogeneity in NIDDM: separate contributions of IRS-1 and b3-adrenergic-receptor mutations to insulin resistance and obesity respectively with no evidence for glycogen synthase gene mutations

  1996cited by this paper
• APOA5 polymorphisms influence plasma triglycerides in young, healthy African Americans and whites of the CARDIA Study

  year unknowncited by this paper

• Analysis of hyperlipidemia risk factors among pilots based on physical examination data: A study using a multilevel propensity score models

  2024cites this paper
• Urine proteomic analysis of patients with schizophrenia

  2023cites this paper
• Coadministration of olanzapine causes minor impacts on the diabetogenic outcomes induced by dexamethasone treatment in rats.

  2023cites this paper
• Olanzapine in the Treatment of Schizophrenia and How Its Response is Modulated by Variations in Certain Genes

  2022cites this paper
• Olanzapine leads to nonalcoholic fatty liver disease through the apolipoprotein A5 pathway

  2021cites this paper
• The pharmacogenetics of treatment with olanzapine.

  2021cites this paper
• Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers.

  2021cites this paper
• Olanzapine inhibits hepatic apolipoprotein A5 secretion inducing hypertriglyceridemia in schizophrenia patients and mice

  2021cites this paper
• Metabolic Effects of Aripiprazole and Olanzapine Multiple-Dose Treatment in a Randomised Crossover Clinical Trial in Healthy Volunteers: Association with Pharmacogenetics

  2020cites this paper
• Cardiovascular Manifestations in Schizophrenia

  2020cites this paper
• Metabolic effects of aripiprazole and olanzapine multiple-dose treatment in healthy volunteers. Association with pharmacogenetics

  2020cites this paper
• Association study of candidate genes with obesity and metabolic traits in antipsychotic-treated patients with first-episode psychosis over a 2-year period

  2020cites this paper
• Altered apolipoprotein C expression in association with cognition impairments and hippocampus volume in schizophrenia and bipolar disorder

  2017cites this paper
• Comparison of metabolic syndrome prevalence in patients with schizophrenia and bipolar I disorder.

  2017cites this paper
• Paper Title: Comparison of Metabolic Syndrome Prevalence in Patients with Schizophrenia and Bipolar I Disorder

  2017cites this paper
• Genetic variation in the miR‐708 gene and its binding targets in bipolar disorder

  2016cites this paper
• A systematic review of genetic variants associated with metabolic syndrome in patients with schizophrenia.

  2016cites this paper
• Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics

  2016cites this paper
• Clozapine safety, 40 years later.

  2014cites this paper
• EPA-1239 – Individualizing Clozapine and Risperidone Treatment For Schizophrenia Patients

  2014cites this paper
• Potential mechanisms of atypical antipsychotic-induced hypertriglyceridemia

  2013cites this paper
• A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patients

  2013cites this paper
• Pharmacogenetics of clinical response to risperidone.

  2013cites this paper
• Pharmacogenetics in schizophrenia: a review of clozapine studies.

  2013cites this paper
• The pharmacogenetics of antipsychotic treatment.

  2012cites this paper
• Pharmacogenetic Aspects of Antipsychotic Drug-induced Weight Gain - A Critical Review

  2012cites this paper
• Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population

  2012cites this paper
• Impact of apolipoprotein A5 (APOA5) polymorphisms on serum triglyceride levels in schizophrenic patients under long-term atypical antipsychotic treatment

  2012influential citation
• Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications

  2012cites this paper
• Autism Treatment Evaluation Checklist

  2012cites this paper
• Toward understanding genetic risk for differential antipsychotic response in individuals with schizophrenia

  2011cites this paper
• Çocuk ve Ergenlerde Atipik Antipsikotik İlaçlarin Metabolik ve Endokrin Yan Etkileri Metabolic and Endocrine Side Effects of Atypical Antipsychotic Drugs in Children and Adolescents

  2011cites this paper
• Çocuk ve Ergenlerde Atipik Antipsikotik İlaçların Metabolik ve Endokrin Yan Etkileri

  2011cites this paper
• A high-carbohydrate diet enhances the adverse effect of the S2 allele of APOC3 SstI polymorphism on the TG/HDL-C ratio only in young Chinese females.

  2011cites this paper
• Allele Frequency of C-482T Polymorphism in Apolipoprotein CIII Gene in a Tehranian Population: Tehran Lipid and Glucose Study

  2010cites this paper
• The promise and reality of pharmacogenetics in psychiatry.

  2010cites this paper
• The promise and reality of pharmacogenetics in psychiatry.

  2010cites this paper
• Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms.

  2010cites this paper
• Chromosome 8p as a potential hub for developmental neuropsychiatric disorders: implications for schizophrenia, autism and cancer

  2009cites this paper
• Implication de l'apolipoprotéine AV dans le déterminisme des hyperchylomicronémies

  2009cites this paper
• Metabolic and Cardiac Side Effects of Second-generation Antipsychotics: What Every Clinician Should Know

  2009cites this paper
• In vivo evidence of differential impact of typical and atypical antipsychotics on intracortical myelin in adults with schizophrenia.

  2009cites this paper
• Genetic variation and antipsychotic drug effects on serum lipids.

  2008influential citation
• Clinical significance of apolipoprotein A5

  2008cites this paper